Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure Buys Cancer Dx Developer Catalyst Oncology for $3M Plus Milestone Payments

NEW YORK (GenomeWeb News) - DiagnoCure today it said has acquired Catalyst Oncology, a Worcester, Mass.-based maker of prognostic tests for breast and colon cancers, for $3 million in cash and stock and potential future payments based on specific milestones.
 
DiagnoCure plans to complete the development of Catalyst's tests and conduct additional clinical studies. The newly acquired tests have already been validated in “multiple clinical studies involving patients with five tumor types," including breast and colon, the company said.
 
The tests, which measure the level of activated tyrosine phosphorylated Shc protein and p66 Shc protein in tissue specimens, have successfully indicated the risk of recurrence of cancer and have predicted the response to cancer therapies, including tamoxifen and traditional chemotherapy, DiagnoCure said.
 
DiagnoCure CEO John Schafer said in a statement that the company’s merger and acquisition strategy is "aimed at building a critical mass of high-value oncology diagnostic products” that will be offered through its CLIA-certified laboratory, which is expected to open later this year.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.